{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T13:06:11Z","timestamp":1780664771829,"version":"3.54.1"},"reference-count":20,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T00:00:00Z","timestamp":1766707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Cutan Med Surg"],"published-print":{"date-parts":[[2026,5]]},"abstract":"\n Objective:<\/jats:title>\n To evaluate efficacy and safety of abrocitinib and dupilumab in the treatment of moderate-to-severe atopic dermatitis (AD).<\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n A retrospective analysis of 104 patients with moderate-to-severe AD (January-June 2023) was conducted. Patients received either oral abrocitinib 200\u2009mg\/day (n\u2009=\u200951) or subcutaneous dupilumab 300\u2009mg every 2\u2009weeks (n\u2009=\u200953, baseline load 600\u2009mg) for 24\u2009weeks.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n At 4, 8, and 12\u2009weeks posttreatment, patients in the abrocitinib group exhibited significantly lower Eczema Area and Severity Index (EASI) scores compared to the dupilumab group (\n P<\/jats:italic>\n \u2009<\u2009.05). Additionally, patients in the abrocitinib group demonstrated significantly lower Numeric Rating Scale for Pruritus (P-NRS) scores at 4, 8, 12, 16, and 24\u2009weeks posttreatment compared to the dupilumab group (\n P<\/jats:italic>\n \u2009<\u2009.05). Furthermore, patients in the abrocitinib group showed significantly lower Dermatology Life Quality Index (DLQI) scores at 4, 8, 12, and 16\u2009weeks posttreatment compared to the dupilumab group (\n P<\/jats:italic>\n \u2009<\u2009.05). Compared with dupilumab group, EASI, P-NRS and DLQI levels in abrocitinib group were more significantly decreased. The incidence of conjunctivitis in dupilumab group was significantly higher than that in abrocitinib group (\n P<\/jats:italic>\n \u2009<\u2009.05). The incidence of nausea in abrocitinib group was significantly higher than that in dupilumab group (\n P<\/jats:italic>\n \u2009<\u2009.05).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion:<\/jats:title>\n Both abrocitinib and dupilumab can significantly relieve pruritus and improve quality of life in patients with moderate-to-severe AD at 24\u2009weeks after treatment, but abrocitinib is more effective in relieving pruritus. Both abrocitinib and dupilumab have high safety, but require attention for gastrointestinal symptoms and conjunctivitis, respectively.<\/jats:p>\n <\/jats:sec>","DOI":"10.1177\/12034754251404468","type":"journal-article","created":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T06:26:01Z","timestamp":1766816761000},"page":"242-248","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Abrocitinib and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis"],"prefix":"10.1177","volume":"30","author":[{"given":"Xinlin","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Dermatology, Renmin Hospital, Hubei University of Medicine, Shiyan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Renmin Hospital, Hubei University of Medicine, Shiyan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Shihezi University, Shihezi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8250-000X","authenticated-orcid":false,"given":"Xue","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Renmin Hospital, Hubei University of Medicine, Shiyan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,12,26]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-021-08880-3"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/cea.14558"},{"issue":"6","key":"e_1_3_2_4_2","first-page":"1135","article-title":"Expert consensus on the systemic treatment of atopic dermatitis in special populations","volume":"37","author":"Adam DN","year":"2023","unstructured":"Adam DN, Gooderham MJ, Beecker JR, et al. Expert consensus on the systemic treatment of atopic dermatitis in special populations. JEADV. 2023;37(6):1135-1148.","journal-title":"JEADV"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11882-024-01145-x"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.3336"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.08.022"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1177\/10600280221096713"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2019380"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.5021\/ad.2019.31.6.654"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v102.3932"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.4103\/0366-6999.178960"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/all.15952"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1610020"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1177\/12034754221130969"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15020385"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30732-7"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.0455"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-022-00819-6"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.04.009"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2202778"}],"container-title":["Journal of Cutaneous Medicine and Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/12034754251404468","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/12034754251404468","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/12034754251404468","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T12:18:59Z","timestamp":1780661939000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/12034754251404468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,26]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1177\/12034754251404468"],"URL":"https:\/\/doi.org\/10.1177\/12034754251404468","relation":{},"ISSN":["1203-4754","1615-7109"],"issn-type":[{"value":"1203-4754","type":"print"},{"value":"1615-7109","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,26]]}}}